Molecure

First-in-class small molecules · Oncology (arginase), IPF

Overview

Formerly OncoArendi. OATD-02 (dual arginase 1/2 inhibitor) in Phase 1 oncology; OATD-01 (chitinase inhibitor) was previously licensed to Galapagos for fibrosis.

What they do

Molecure, formerly OncoArendi Therapeutics, is a Warsaw Stock Exchange-listed biotech developing first-in-class small molecules against enzyme and RNA targets in oncology and fibrosis. The company runs in-house discovery and is known for focusing on novel mechanisms rather than fast-follower chemistry.

Lead program & status

Its clinical lead, OATD-02, is an oral, selective, first-in-class dual arginase 1/2 inhibitor for cancer. The first-in-human Phase I trial dosed its first patient in early 2023; the company reported no dose-limiting toxicities during dose escalation and, in early 2025, after a positive Safety Review Committee recommendation, amended the protocol to test higher doses than originally planned. Its second asset, OATD-01, a dual chitinase inhibitor, had been licensed to Galapagos for fibrosis; Molecure regained worldwide rights at no cost in 2022 and has signaled intent to develop it in sarcoidosis, its originally preferred indication, via a Phase II proof-of-concept study. As of 2024 the company narrowed its earlier discovery programs to concentrate resources on these clinical assets.

Why it matters

OATD-02 is among the few clinical-stage dual arginase inhibitors globally, positioning Molecure in immuno-metabolic oncology, while regaining OATD-01 gives it a second wholly owned, clinically validated mechanism in inflammation and fibrosis.

FAQ

Was Molecure previously called something else?

Yes. Molecure was formerly known as OncoArendi Therapeutics and is listed on the Warsaw Stock Exchange.

What is OATD-02?

OATD-02 is Molecure's lead candidate, an oral first-in-class dual arginase 1/2 inhibitor in a Phase I oncology trial; the company reported no dose-limiting toxicities during dose escalation.

What happened with the Galapagos deal for OATD-01?

Molecure had licensed the dual chitinase inhibitor OATD-01 to Galapagos for fibrosis but regained full worldwide rights at no cost in 2022, and has indicated plans to develop it in sarcoidosis.

Company website / source ↗ Open the interactive map →